checkAd

     1069  0 Kommentare Iris BioTechnologies Welcomes New Board Member and Key Employees

    SANTA CLARA, CA--(Marketwired - January 27, 2015) - Iris BioTechnologies Inc. (OTCQB: IRSB), a life sciences company poised to set new personalized medicine standards for precision diagnosis and therapy, is pleased to welcome Dr. Douglas Hendren, Dr. John Hearst, Dr. Frank Chuang, and Gayle Murray to our team at a very exciting time in the growth of our company. In the State of the Union speech on January 20, 2015, President Obama said, "Personalized medicine represents a revolutionary and exciting change in the fundamental approach and practice of medicine."

    Douglas Hendren, M.D., MBA, was elected to the Iris Board of Directors along with existing board members Simon Chin and Grace Osborne at the Iris annual shareholders meeting. Dr. Hendren served as Medical and Business Strategy Advisor since October 2013. Doug was a partner at Humboldt Orthopedics. He was a founding partner of Hess Orthopaedics, a managing partner, designer and the first director of the Hess surgical facility. Dr. Hendren obtained a B.A. from Harvard University and an M.D. from Case Western Reserve University. Doug also completed the Harvard Orthopaedic Program and received an M.B.A. from Bainbridge Graduate Institute.

    John Hearst, Ph.D., has been appointed to the newly created position of Director of Clinical Chemistry. John is an Emeritus Professor of Chemistry at U.C. Berkeley. He was previously the Founding Director and Vice President for New Science Opportunities at Cerus Corporation. The Hearst Lab at U.C. Berkeley started out doing biophysical structure studies of DNA, looking at the elasticity of DNA and the physical processes of DNA transcription and replication. Dr. Hearst attracted students who wanted to work on the cutting edge.

    Dr. Hearst mentored 65 graduate students, including Dr. Thomas Cech, who became a Nobel Laureate in Chemistry and the President of the Howard Hughes Medical Institute. Dr. Hearst received his B.E. from Yale University and Ph.D. from California Institute of Technology. John was Director of Chemical Biodynamics Division, Lawrence Berkeley Laboratory and Recipient of Berkeley Citation, University of California, Berkeley. Dr. Hearst also received the Mortimer M. Bortin Award for Outstanding Research in Bone Marrow Transplant.

    Frank Chuang, Ph.D., M.D., has been appointed to the newly created position of Director of Clinical Applications. In this role, he will have broad responsibilities in clinical translation research and launching new products. Dr. Chuang received his B.S. in Bioengineering from U.C. Berkeley and Ph.D., M.D. in Biophysics and Immunobiology from City University of New York and the Mount Sinai School of Medicine. He previously worked at Cornell Hospital for Special Surgery in rheumatologic disease, the Lawrence Livermore National Laboratory in their Medical Technology Program, and the Comprehensive Cancer Center, University of California, Davis. Dr. Chuang's research experience includes advanced biodetection technologies and in vitro diagnostics. As a faculty member in Biochemistry and Molecular Medicine and Associate Director of Center for Biophotonics in the UC Davis Health System, Frank has been leading the development of new technologies for medical and other life science applications.

    Seite 1 von 3



    Verfasst von Marketwired
    Iris BioTechnologies Welcomes New Board Member and Key Employees SANTA CLARA, CA--(Marketwired - January 27, 2015) - Iris BioTechnologies Inc. (OTCQB: IRSB), a life sciences company poised to set new personalized medicine standards for precision diagnosis and therapy, is pleased to welcome Dr. Douglas Hendren, …